









市場行情
/
股票
/
nasdaq-pcvx
/

Vaxcyte Inc

PCVX

47.650USD

-0.160-0.33%

收盤 12/24, 16:00（美東）報價延遲15分鐘

6.20B總市值

虧損本益比TTM



Vaxcyte Inc

47.650

-0.160-0.33%

概覽公司財務分析

概覽

公司

財務

分析

關於 Vaxcyte Inc 公司

Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

Vaxcyte Inc簡介



公司代碼PCVX

公司名稱Vaxcyte Inc

上市日期Jun 12, 2020

CEOPickering (Grant E)

員工數量414

證券類型Ordinary Share

年結日Jun 12

公司地址825 Industrial Road, Ste. 300

城市SAN CARLOS

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94070

電話16508370111

網址https://vaxcyte.com/

公司代碼PCVX

上市日期Jun 12, 2020

CEOPickering (Grant E)

Vaxcyte Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Grant E. Pickering

Chief Executive Officer, Co-Founder, Director

658.46K

-2.69%

Mr. Andrew L. Guggenhime

President, Chief Financial Officer

75.59K

-9.54%

Mr. James (Jim) Wassil

Executive Vice President, Chief Operating Officer

27.26K

-20.53%

Mr. Mikhail Eydelman, J.D.

Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary

12.60K

-28.82%

Dr. Carlos V. Paya, M.D., Ph.D.

Independent Chairman of the Board

8.67K

+54.06%

Ms. Teri Loxam

Independent Director

8.67K

+54.06%

Mr. Jacks Lee

Independent Director

3.04K

Mr. John P. Furey

Independent Director

3.04K

Dr. Olivier Brandicourt

Independent Director

1.15K

Dr. Heath Lukatch, Ph.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Grant E. Pickering

Chief Executive Officer, Co-Founder, Director

658.46K

-2.69%

Mr. Andrew L. Guggenhime

President, Chief Financial Officer

75.59K

-9.54%

Mr. James (Jim) Wassil

Executive Vice President, Chief Operating Officer

27.26K

-20.53%

Mr. Mikhail Eydelman, J.D.

Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary

12.60K

-28.82%

Dr. Carlos V. Paya, M.D., Ph.D.

Independent Chairman of the Board

8.67K

+54.06%

Ms. Teri Loxam

Independent Director

8.67K

+54.06%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月15日週六

持股股東

股東類型

持股股東

佔比

Janus Henderson Investors

10.01%

The Vanguard Group, Inc.

9.39%

RA Capital Management, LP

9.14%

Fidelity Management & Research Company LLC

7.90%

BlackRock Institutional Trust Company, N.A.

6.41%

其他

57.15%

持股股東

佔比

Janus Henderson Investors

10.01%

The Vanguard Group, Inc.

9.39%

RA Capital Management, LP

9.14%

Fidelity Management & Research Company LLC

7.90%

BlackRock Institutional Trust Company, N.A.

6.41%

其他

57.15%

股東類型

持股股東

佔比

Investment Advisor

43.44%

Investment Advisor/Hedge Fund

31.40%

Hedge Fund

19.35%

Venture Capital

11.37%

Research Firm

2.23%

Bank and Trust

0.97%

Sovereign Wealth Fund

0.75%

Individual Investor

0.68%

Pension Fund

0.61%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

668

148.53M

114.41%

-14.14M

2025Q2

654

150.97M

116.29%

-1.23M

2025Q1

669

149.26M

115.73%

-5.52M

2024Q4

629

143.44M

111.44%

-3.61M

2024Q3

579

138.80M

114.99%

+5.28M

2024Q2

508

125.57M

113.86%

-5.08M

2024Q1

487

122.06M

113.01%

+8.05M

2023Q4

444

106.09M

111.72%

-6.02M

2023Q3

417

110.70M

121.97%

-7.51M

2023Q2

397

109.13M

122.07%

+11.09M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Janus Henderson Investors

14.69M

11.32%

+151.06K

+1.04%

Jun 30, 2025

The Vanguard Group, Inc.

11.97M

9.22%

-48.12K

-0.40%

Jun 30, 2025

RA Capital Management, LP

11.97M

9.22%

-223.16K

-1.83%

Jun 30, 2025

Fidelity Management & Research Company LLC

10.05M

7.74%

-677.06K

-6.31%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

9.05M

6.97%

-85.53K

-0.94%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

6.00M

4.62%

+3.30M

+122.04%

Jun 30, 2025

Wellington Management Company, LLP

4.95M

3.82%

-1.46M

-22.79%

Jun 30, 2025

State Street Investment Management (US)

4.94M

3.81%

+534.55K

+12.13%

Jun 30, 2025

D. E. Shaw & Co., L.P.

3.09M

2.38%

+2.22M

+255.86%

Jun 30, 2025

Paradigm BioCapital Advisors LP

3.37M

2.6%

+1.68M

+98.81%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Harbor Health Care ETF

4.32%

ALPS Medical Breakthroughs ETF

2.39%

State Street SPDR S&P Biotech ETF

1.65%

Direxion Daily S&P Biotech Bull 3X Shares

1.02%

Virtus LifeSci Biotech Clinical Trials ETF

0.89%

ProShares Ultra Nasdaq Biotechnology

0.58%

Invesco Nasdaq Biotechnology ETF

0.57%

iShares Biotechnology ETF

0.5%

JPMorgan Fundamental Data Science Small Core ETF

0.44%

iShares Russell 2000 Value ETF

0.34%

Harbor Health Care ETF

佔比4.32%

ALPS Medical Breakthroughs ETF

佔比2.39%

State Street SPDR S&P Biotech ETF

佔比1.65%

Direxion Daily S&P Biotech Bull 3X Shares

佔比1.02%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.89%

ProShares Ultra Nasdaq Biotechnology

佔比0.58%

Invesco Nasdaq Biotechnology ETF

佔比0.57%

iShares Biotechnology ETF

佔比0.5%

JPMorgan Fundamental Data Science Small Core ETF

佔比0.44%

iShares Russell 2000 Value ETF

佔比0.34%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Vaxcyte Inc的前五大股東是誰？



Vaxcyte Inc的前五大股東如下：
Janus Henderson Investors
持有股份：14.69M
佔總股份比例：11.32%。
The Vanguard Group, Inc.
持有股份：11.97M
佔總股份比例：9.22%。
RA Capital Management, LP
持有股份：11.97M
佔總股份比例：9.22%。
Fidelity Management & Research Company LLC
持有股份：10.05M
佔總股份比例：7.74%。
BlackRock Institutional Trust Company, N.A.
持有股份：9.05M
佔總股份比例：6.97%。